Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense growth accelerates

Q1 FY2026 income tax expense of $3M rose 4520.0% year over year, ahead of the -25708.8% change in trailing-twelve-month income tax expense.

Context

  • Income tax expense amounted to 83.3% of revenue in FY2025, up 82.8 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4520.0% holds above the trailing-twelve-month pace of -25708.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3M+101.2% QoQ
Last fiscal yearDec 2025
-$245.2M-27931.7% YoY
LTMMar 2026
-$242.26M-25708.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4520.0%——
1 year-27931.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(245.2M) USD
Year-over-year change
-27931.7%

Income Tax Expense vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 income tax expense of -$242.26M is the lowest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -25708.8% is the lowest of 7, against a peer median of -3.4%.
  • Income tax expense amounts to 80.8% of revenue for RIGL, versus a peer median of 1.9%.
RIGL Competitors Peer median
Income Tax Expense for RIGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EXELExelixis, Inc.LTM Jul 2026$174.84M +0.9%+45.0%7.2%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$13.34M +1636.3%—1.9%
ANLAdlai Nortye Ltd.LTM Jun 2024$643K ——9.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$121K -7.6%—0.3%
VSTMVerastem, Inc.LTM Mar 2026$0 -100.0%—0.0%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 -100.0%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026$0 ———
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 ——0.0%
MREOMereo BioPharma Group plcLTM Mar 2026-$94.84K +83.4%—19.0%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026-$242.26M -25708.8%—80.8%
Peer median (excluding RIGL) $0-3.4%+45.0%1.9%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue149.24M120.24M116.88M179.28M294.28M
Cost of Revenue1.08M1.75M7.11M18.65M19.62M
Gross Profit148.15M118.49M109.77M160.63M274.66M
Gross Margin99.3%98.5%93.9%89.6%93.3%
Research & Development65.24M60.27M24.52M23.38M33.3M
Selling, General & Admin91.89M112.45M105.74M113.06M115.9M
Operating Expenses160.65M174.04M130.26M136.44M149.2M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
EBITDA(11.29M)(53.87M)(16.98M)28.51M131.56M
EBITDA Margin-7.6%-44.8%-14.5%15.9%44.7%
Operating Income(12.5M)(55.55M)(20.49M)24.19M125.47M
Operating Margin-8.4%-46.2%-17.5%13.5%42.6%
Interest Income47K684K2.27M2.09M3.68M
Interest Expense4.86M3.71M6.87M7.92M7.32M
Other Income / Expenses(4.81M)(3.02M)(4.6M)(5.83M)(3.64M)
Income Before Tax(17.31M)(58.57M)(25.09M)18.37M121.83M
Pre-Tax Margin-11.6%-48.7%-21.5%10.2%41.4%
Income Tax Expense605K00881K(245.2M)
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Net Margin-12.0%-48.7%-21.5%9.8%124.7%
EPS (Basic)(1.10)(3.40)(1.44)0.9920.40
EPS (Diluted)(1.10)(3.40)(1.44)0.9919.48
Weighted Avg Shares17.05M17.24M17.4M17.58M17.99M
Weighted Avg Shares (Diluted)17.05M17.24M17.4M17.69M18.84M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.